Fig. 2From: Clinical trial considerations on male contraception and collection of pregnancy information from female partner: updateSafety margin estimations: monoclonal antibodies. AUC area under the curve, C max maximum concentration, C semen seminal concentration, EFD embryo-fetal development, mAb monoclonal antibody, MABEL minimum anticipated biological effect level, NOAEL no adverse effect levelBack to article page